Snapshot · Merck & Co., Inc. (MRK)

Data as of 2026-09-01T03:32:14.667Z

Fundamentals check

Market cap

$364.9B

P/E (TTM)

117.3

Gross margin

75.4%

Net margin

4.8%

ROE

6.6%

R&D / revenue

42.7%

Dividend yield

2.3%

FCF yield

4.4%

Latest dividend: $0.85/share (ex-date 2026-09-15, quarterly)

Summary

Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.

How it makes money

Revenue mix, latest fiscal year

• Pharmaceutical segment89.4%
• Animal Health segment9.8%
• Other Segments0.8%

Recent Events

• 2026-08-28T06:02:57.000Zpositive

  Success after a century of failures: Inside Moderna and Merck's cancer vaccine breakthrough

  恰逢莫德纳/默沙东癌症疫苗取得突破，可能与 MRK 的相关性存在不确定性，需进一步观察市场影响。

  Source: reuters.com

• 2026-08-26T10:55:43.000Zpositive

  Merck Stock Hits New 52-Week High: What's Driving the Rally?

  恰逢股价创一年新高，可能与 melanoma 数据及管线进展相关，具体因果尚不明确。

  Source: zacks.com

• 2026-08-26T05:07:57.000Zneutral

  Merck & Co., Inc. $MRK Shares Acquired by BlackRock Inc.

  黑岩增持 MRK 股份，可能与投资者信心相关，但未必直接导致股价变化的因果，需更多证据。

  Source: defenseworld.net

• 2026-08-19T00:00:00.000Zpositive

  Price move: MRK rose 12.6%

  MRK 在这段行情中出现明显波动，恰逢异常的价格变动，但此处没有可关联到的具体新闻事件。

• 2026-07-16T00:00:00.000Zpositive

  Price move: MRK rose 3.3%

  MRK 在这段行情中出现明显波动，恰逢异常的价格变动，但此处没有可关联到的具体新闻事件。

• 2026-07-02T00:00:00.000Zpositive

  Price move: MRK rose 3.3%

  MRK 在这段行情中出现明显波动，恰逢异常的价格变动，但此处没有可关联到的具体新闻事件。

• 2026-06-25T00:00:00.000Zpositive

  Price move: MRK rose 4.0%

  MRK 在这段行情中出现明显波动，恰逢异常的价格变动，但此处没有可关联到的具体新闻事件。

• 2026-06-04T00:00:00.000Zpositive

  Price move: MRK rose 4.8%

  MRK 在这段行情中出现明显波动，恰逢异常的价格变动，但此处没有可关联到的具体新闻事件。

Analyst view

Avg price target $150.6 from 20 analysts (last quarter)

Recent rating changes

• 2026-08-20 · Morgan Stanley Upgraded → Overweight
• 2026-08-20 · RBC Capital Downgraded → Sector Perform

Insider & Congress activity

Open-market trades only; grants and exercises excluded

• 2026-08-13SellGuindo Chirfi(officer: EVP, Access, Policy & Comms)10,000 shares
• 2026-08-12SellDeLuca Richard R.(officer: EVP&Pres, Merck Animal Heallth)600 shares
• 2026-08-12SellDeLuca Richard R.(officer: EVP&Pres, Merck Animal Heallth)11,099 shares
• 2026-08-12SellZachary Jennifer(officer: EVP, General Counsel)80,315 shares
• 2026-08-11SellDeLuca Richard R.(officer: EVP&Pres, Merck Animal Heallth)5,427 shares

订阅每日简报

每个交易日开盘/收盘后，中文市场简报直达邮箱。免费，随时退订。

本内容仅为信息整理，不构成任何投资建议。